AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01966042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells infusion
Description: Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
Study NCT00004143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Chemo and/or TBI Allo SCT
Description: Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
Study NCT00232115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %
Study NCT00232115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle cream (placebo)
Study NCT00567281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid 2 system triggering Magstim Super Rapid system
Description: Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
Study NCT00567281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid-2 system triggering Magstim Super Rapid system
Description: Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
Study NCT02453425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP 60 mmHg
Description: Norepinephrine adjusted to reach MAP 60 mmHg
Study NCT02453425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP 75 mmHg
Description: Norepinephrine adjusted to reach MAP 75 mmHg
Study NCT02208362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Correlative studies
Study NCT02453425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP 90 mmHg
Description: Norepinephrine adjusted to reach MAP 90 mmHg
Study NCT03385746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyamide
Description: metal reinforced polyamide denture base material
Study NCT01804101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cytarabine-Daunorubicin CPX-351
Description: Given IV
Study NCT03385746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heat cured acrylic resin
Description: conventional heat cured acrylic resin denture base material
Study NCT03850509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071
Description: OPS-2071 300 mg, tablets, orally, BID.
Study NCT03850509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OPS-2071-matched placebo, tablets, orally, BID.
Study NCT01329419 — intervention group
Intervention type: DRUG
Intervention: adefovir dipivoxil
Description: Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT02208362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04594369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Description: Oral tablet.
Study NCT04594369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Description: Oral tablet.
Study NCT04594369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Brensocatib-matching oral tablet.
Study NCT03892174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol with adsorption
Description: Adsorption while patients are in the OR on the extracorporeal circuit
Study NCT00656604 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: at the time of each procedure.
Study NCT00656604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumpectomy or mastectomy
Description: removal of breast tumor or removal of the entire breast in which the tumor is located
Study NCT00656604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Prior to initiation of treatment
Study NCT00656604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histopathologic examination
Description: After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
Study NCT00656604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopy
Description: Prior to initiation of treatment
Study NCT04209725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Given during the induction and consildation phase and will consist of 44 mg/m\^2 daunorubicin with 100 mg/m\^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
Study NCT04209725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
Study NCT01232010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil
Description: 50mg Single Oral Dose of
Study NCT03257332 — intervention group
Intervention type: PROCEDURE
Intervention: Low Anterior Resection for Rectum Cancer
Description: Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
Study NCT00114179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00114179 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00114179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00114179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00114179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT03233802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Assess & Treatment (IATP)
Description: See previous description
Study NCT03233802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Packaged Cognitive-Behavioral (PCBT)
Description: See previous description
Study NCT03233802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management (CaseM)
Description: See previous description
Study NCT02605564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Free Diet
Description: Gluten Free Diet
Study NCT02605564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo No intervention, standard T1DM diet
Study NCT03535064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Hygiene Workshop
Description: Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
Study NCT04265742 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bone densitometry
Description: Bone Mineral Density (BMD), body composition, vertebral fractures
Study NCT02278939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Filipinos Fit and Trim Weight Loss Program
Description: This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
Study NCT02278939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Filipinos Fit and Trim Weight Loss Program
Description: This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
Study NCT02650258 — intervention group
Intervention type: BEHAVIORAL
Intervention: treadmill walking
Description: all participants walking at increasing speeds on a treadmill
Study NCT04265742 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High resolution peripheral QCT
Description: High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.0025% PEP005 Topical Gel (Day 1,2 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.01% PEP005 Topical Gel (Day 1,2 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.05% PEP005 Topical Gel (Day 1,2 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEP005
Description: Vehicle Gel (Day 1,2 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.0025% PEP005 Topical Gel (Day 1,8 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.01% PEP005 Topical Gel (Day 1,8 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.05% PEP005 Topical Gel (Day 1,8 application)
Study NCT00107965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEP005
Description: Vehicle Gel (Day 1,8 application)
Study NCT02501954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02501954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02501954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT02501954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02501954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02501954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo Radiation Therapy
Study NCT02501954 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo Radiation Therapy
Study NCT04265742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
Study NCT01237041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin First
Description: Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day
Study NCT01237041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo First
Description: Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day
Study NCT01237041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Establishing Study 1 Niacin 250mg
Description: Niacin 250 mg po three times at 2 hour intervals on an inpatient day
Study NCT01237041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Establishing Study 1 Niacin 500mg
Description: Niacin 500 mg po three times at 2 hour intervals on an inpatient day
Study NCT01237041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Establishing Study 2 Niacin 500mg
Description: Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
Study NCT04265742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Epidemiologic and nutritional questionnaire and physical activity scale
Study NCT02772172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Template
Study NCT04726072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Description: Participants met once a week for two hours for 12 weeks total. The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises, and meditation. Participants were also asked to do at-home practice for half an hour daily.
Study NCT04265742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical tests
Description: physical performance tests and grip strenght measurement
Study NCT04726072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants met once a week for two hours for 10 weeks total. The psychoeducation group acted as our control group and consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily.
Study NCT05672680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Description: received during TAP block
Study NCT05672680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo equivalent
Study NCT02390726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Study NCT02390726 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study NCT03116984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
Study NCT03116984 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External- beam radiotherapy
Description: We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
Study NCT01487980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord clamping
Description: Early vs Delayed
Study NCT01487980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cord clamping
Description: Early vs Delayed
Study NCT00679328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical implantation of OP-1 device or autograft bone graft material
Description: Surgical implantation of OP-1 device or autograft bone graft material
Study NCT00679328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical implantation of OP-1 device or autograft bone graft material
Description: Surgical implantation of OP-1 device or autograft bone graft material
Study NCT01133158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Bendamustine, Mitoxantrone, Dexamethasone
Description: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
Study NCT03721575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scarpa's preserving hernio-abdominoplasty
Description: Scarpa's fascia is preserved during hernio-abdominoplasty
Study NCT03721575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical hernio-abdominoplasty
Description: Scarpa's fascia is removed during hernio-abdominoplasty
Study NCT05462535 — intervention group
Intervention type: DRUG
Intervention: Amosartan Plus Tab.
Description: Amosartan Plus Tab., Once daily administered per the locally approved product information
Study NCT02470130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 5 min of conversational relaxation red by one of the instructor between simulation and debriefing
Study NCT00658567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 10 mg, tablet, once daily by mouth, for six weeks
Study NCT00658567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 20 mg, tablet, once daily by mouth, for six weeks
Study NCT00658567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimavanserin tartrate (ACP-103)
Description: Placebo, tablet, once daily by mouth, for six weeks
Study NCT00831064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy bowel prep
Description: PEG, bisacodyl, NaP, PSMC and Mg-citrate
Study NCT03761303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS
Description: The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
Study NCT03761303 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
Study NCT03264651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enobosarm
Description: Oral combination therapy of enobosarm and anastrozole
Study NCT04031482 — intervention group
Intervention type: OTHER
Intervention: No intervention, only standard care
Description: The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~* analyse disease progression~* systematize findings about treatment processes~* identify potential influencing factors~* review any new diagnostic procedures~* identify potential test subjects for further study~* evaluate the safety of various treatment concepts